Magnitude of Phenotypic and MTBDRplus Line Probe Assay First-Line Anti-Tuberculosis Drug Resistance Among Tuberculosis Patients; Northwest Ethiopia
Open Access
- 1 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Infection and Drug Resistance
- Vol. ume 14, 497-505
- https://doi.org/10.2147/idr.s292058
Abstract
Background: Mycobacterium tuberculosis (Mtb) drug resistance is a key challenge in ending TB. Objective: The study aimed to determine anti-TB drug resistance and compare the discordance between phenotypic and genotypic drug-susceptibility testing (DST). Methods: Prospective enrollment and sputum collection from patients suspected of active pulmonary TB from May 2018 to December 2019 at the University of Gondar Hospital. Phenotypic DST study for streptomycin, isoniazid, rifampin, and ethambutol was done by MGIT 360 SIRE Kit. Genotypic resistance for isoniazid and rifampin was performed by MTBDRplus v2 line probe assay (LPA) and compared to phenotypic drug resistance. Results: A total of 376 patients, median age 32 years, and 53.7% male were enrolled. Mtb was isolated from 126 patients. 106/126 (84%) patients were newly diagnosed with TB and 20 patients with prior TB treatment. Seventy (66.0%) were susceptible to all anti‐TB drugs tested. Twenty-five (19.8%) of the isolates were resistant to isoniazid, 12 (9.5%) to rifampicin and six (5%) were multidrug resistant. Among previously treated TB patients, 4 (20.0%) and 5 (25.0%) were mono-resistant and poly-resistant, respectively. The sensitivity and specificity of LPA resistance for isoniazid were 94.4% and 100%, and for rifampin was 75.0% and 100%, respectively. Conclusion: The frequency of mono- and poly-drug resistance among both newly diagnosed and previously treated TB patients was high to the rest of the nation. MTBDRplus showed excellent concordance for isoniazid and rifampin. We concluded that DST should be performed for all patients to improve management and decrease spread of drug-resistant Mtb strains in the community.Keywords
This publication has 34 references indexed in Scilit:
- Molecular and Growth-Based Drug Susceptibility Testing ofMycobacterium tuberculosisComplex for Ethambutol Resistance in the United StatesTuberculosis Research and Treatment, 2016
- Phenotypic and Genotypic Analysis of Anti-Tuberculosis Drug Resistance in Mycobacterium tuberculosis Isolates in MyanmarAnnals of Laboratory Medicine, 2015
- Characterization of phenotypic and genotypic drug resistance patterns of Mycobacterium tuberculosis isolates from a city in MexicoEnfermedades Infecciosas y Microbiología Clínica, 2015
- Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challengesClinical Medicine, 2014
- Drug Resistance Pattern of Mycobacterium tuberculosis in Eastern Amhara Regional State, EthiopiaJournal of Microbial & Biochemical Technology, 2014
- Seroprevalence of Toxoplasma gondiiand associated risk factors among pregnant women in Jimma town, Southwestern EthiopiaBMC Infectious Diseases, 2012
- Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, EthiopiaBMC Research Notes, 2012
- First- and second-line anti-tuberculosis drug resistance in Northwest EthiopiaThe International Journal of Tuberculosis and Lung Disease, 2012
- High content live cell imaging for the discovery of new antimalarial marine natural productsBMC Infectious Diseases, 2012
- Antituberculosis Drug Resistance in the South of Vietnam: Prevalence and TrendsThe Journal of Infectious Diseases, 2006